|
Category:pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | WHITE crystalline powder (est) |
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 229.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 534.46 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 531.00 °F. TCC ( 277.00 °C. ) (est)
|
| logP (o/w): | -2.191 (est) |
| Soluble in: |
| | water, 8.894e+004 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-bird - wild LD50 100 mg/kg
Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
intravenous-dog LD50 7200 ug/kg
BLOOD: OTHER CHANGES
Advances in Pharmacology and Chemotherapy. Vol. 14, Pg. 285, 1977.
intraperitoneal-mouse LD50 68 mg/kg
Experientia. Vol. 22, Pg. 53, 1966.
intravenous-mouse LD50 229 mg/kg
BEHAVIORAL: ATAXIA
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
National Technical Information Service. Vol. PB84-211432
oral-mouse LD50 572 mg/kg
Toxicology and Applied Pharmacology. Vol. 19, Pg. 382, 1971.
oral-quail LD50 > 100 mg/kg
Ecotoxicology and Environmental Safety. Vol. 6, Pg. 149, 1982.
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | pharmaceuticals / chemical synthisis |
| Recommendation for azacitidine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for azacitidine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 9444 |
| Pubchem (sid): | 134975625 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| 4- | amino-1-(b-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one | | 4- | amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one | | 4- | amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-1,3,5-triazin-2(1H)-one | | 4- | amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2(1H)-one | | 4- | amino-1-b-D-ribofuranosyl-1,3,5-triazin-2(1H)-one | | | azacitidinum | | | azacytidine | | 5-aza | cytidine | | aza | cytidine, 5- | | 1-[(4S,2R,3R,5R)-3,4- | dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-amino-1,3,5-triazin-2-one | | | ladakamycin | | | mylosar | | 1,3,5- | triazin-2(1H)-one, 4-amino-1-b-D-ribofuranosyl- |
Articles:
| PubMed:Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. |
| PubMed:Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. |
| PubMed:Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. |
| PubMed:Azacitidine in the management of patients with myelodysplastic syndromes. |
| PubMed:FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. |
| PubMed:Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. |
| PubMed:Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. |
| PubMed:Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. |
| PubMed:The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma. |
| PubMed:Lower gastric secretion and higher incorporation of orotic acid into liver RNA in rats treated with 5-azacytidine and cycloheximide. |
| PubMed:Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. |
| PubMed:Vitamin A and beta-carotene inhibitory effect during 1,2-dimethylhydrazine induced hepatocarcinogenesis potentiated by 5-azacytidine. |
| PubMed:Inhibition of aflatoxin metabolism and growth of Aspergillus flavus in liquid culture by a DNA methylation inhibitor. |
| PubMed:Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. |
| PubMed:Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). |
| PubMed:Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? |
| PubMed:Chemical induction of endogenous retrovirus particles from the vero cell line of African green monkeys. |
| PubMed:Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. |
| PubMed:Development of phenotypic screening assays for γ-globin induction using primary human bone marrow day 7 erythroid progenitor cells. |
| PubMed:Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. |
| PubMed:Advances in myelodysplastic syndrome: nursing implications of azacitidine. |
| PubMed:Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. |
| PubMed:Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. |
| PubMed:Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. |
| PubMed:Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome. |
| PubMed:Reprogramming of pig dermal fibroblast into insulin secreting cells by a brief exposure to 5-aza-cytidine. |
| PubMed:The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. |
| PubMed:Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation. |
| PubMed:DNA demethylation and invasive cancer: implications for therapeutics. |
| PubMed:Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. |
| PubMed:Folate deficiency induces dysfunctional long and short telomeres; both states are associated with hypomethylation and DNA damage in human WIL2-NS cells. |
| PubMed:Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. |
| PubMed:Discovery of drugs that possess activity against feline leukemia virus. |
| PubMed:Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. |
| PubMed:MutS HOMOLOG1-derived epigenetic breeding potential in tomato. |
| PubMed:Current status of epigenetic treatment in myelodysplastic syndromes. |
| PubMed:Silencing of Wnt5a during colon cancer metastasis involves histone modifications. |
| PubMed:Developmental toxicity and psychotoxicity of potassium iodide in rats: a case for the inclusion of behaviour in toxicological assessment. |
| PubMed:Pharmacotherapy of myelodysplastic syndromes. |
| PubMed:Current and novel therapeutic approaches in myelodysplastic syndromes. |
| PubMed:DNA methyltransferases as targets for cancer therapy. |
| PubMed:Myelodysplastic Syndromes: Diagnosis and Treatment. |
| PubMed:Use of hypomethylating agents in myelodysplastic syndromes. |
| PubMed:Allele-specific, age-dependent and BMI-associated DNA methylation of human MCHR1. |
| PubMed:Epigenetics and oncology. |
| PubMed:Epigenetic drugs against cancer: an evolving landscape. |
| PubMed:MDS: Refining existing therapy through improved biologic insights. |
| PubMed:DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. |
| PubMed:Character of the stimulatory response of uridine kinase in rat livers to cycloheximide treatment. |
| PubMed:Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. |
| PubMed:Early detection of endogenous retroviruses in chemically induced mouse cells. |
| PubMed:Epigenetic regulation of reelin and brain-derived neurotrophic factor genes in long-term potentiation in rat medial prefrontal cortex. |
| PubMed:DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. |
| PubMed:Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. |
| PubMed:Optimal sequencing of treatments for patients with myelodysplastic syndromes. |
| PubMed:Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. |
| PubMed:Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. |
| PubMed:DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. |
| PubMed:Lycopene and apo-10'-lycopenal do not alter DNA methylation of GSTP1 in LNCaP cells. |
| PubMed:Decitabine. |
| PubMed:Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia? |
| PubMed:Risk-based management of myelodysplastic syndrome. |
| PubMed:Decitabine and its role in the treatment of hematopoietic malignancies. |
| PubMed:Developmental toxicity and psychotoxicity of sodium nitrite in rats. |
| PubMed:Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. |
| PubMed:New treatment for rare bone marrow condition. |
| PubMed:Hematopoietic growth factors in myelodysplastic syndromes. |
| PubMed:Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. |
| PubMed:New approaches to the treatment of myelodysplasia. |
| PubMed:DNA methylation and cancer therapy: new developments and expectations. |
| PubMed:How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. |
| PubMed:Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. |
| PubMed:Salmonella typhimurium strain TA100 differentiates several classes of carcinogens and mutagens by base substitution specificity. |
| PubMed:Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. |
| PubMed:Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. |
| PubMed:Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. |
| PubMed:Acute myeloid leukemia and myelodysplastic syndromes in older patients. |
| PubMed:Targeted therapies in myelodysplastic syndrome. |
| PubMed:Antiangiogenic therapy in myelodysplastic syndromes: is there a role? |
| PubMed:Novel agents for the management of myelodysplastic syndromes. |
|
3D/inchi